UA61897C2 - Protein kinase c inhibitors, methods for synthesis, pharmaceutical formulations and methods for treating microvascular diabetic complications - Google Patents

Protein kinase c inhibitors, methods for synthesis, pharmaceutical formulations and methods for treating microvascular diabetic complications Download PDF

Info

Publication number
UA61897C2
UA61897C2 UA98052515A UA98052515A UA61897C2 UA 61897 C2 UA61897 C2 UA 61897C2 UA 98052515 A UA98052515 A UA 98052515A UA 98052515 A UA98052515 A UA 98052515A UA 61897 C2 UA61897 C2 UA 61897C2
Authority
UA
Ukraine
Prior art keywords
salt
water
compound
solvent
formula
Prior art date
Application number
UA98052515A
Other languages
English (en)
Ukrainian (uk)
Inventor
Michael Robert Jeerousek
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of UA61897C2 publication Critical patent/UA61897C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
UA98052515A 1995-11-20 1996-11-18 Protein kinase c inhibitors, methods for synthesis, pharmaceutical formulations and methods for treating microvascular diabetic complications UA61897C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US697095P 1995-11-20 1995-11-20
PCT/US1996/018512 WO1997018809A1 (en) 1995-11-20 1996-11-18 Protein kinase c inhibitor

Publications (1)

Publication Number Publication Date
UA61897C2 true UA61897C2 (en) 2003-12-15

Family

ID=21723527

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98052515A UA61897C2 (en) 1995-11-20 1996-11-18 Protein kinase c inhibitors, methods for synthesis, pharmaceutical formulations and methods for treating microvascular diabetic complications

Country Status (34)

Country Link
US (3) US5710145A (de)
EP (1) EP0776895B1 (de)
JP (1) JP3348859B2 (de)
KR (1) KR100304210B1 (de)
CN (1) CN1093759C (de)
AR (2) AR004336A1 (de)
AT (1) ATE172199T1 (de)
AU (1) AU711125B2 (de)
BR (1) BR9611724A (de)
CA (1) CA2237221C (de)
CO (1) CO4750823A1 (de)
CY (1) CY2103B1 (de)
CZ (1) CZ297524B6 (de)
DE (1) DE69600784T2 (de)
DK (1) DK0776895T3 (de)
EA (1) EA000967B1 (de)
EG (1) EG23871A (de)
ES (1) ES2122764T3 (de)
HU (1) HU226821B1 (de)
IL (1) IL124417A (de)
MX (1) MX9803792A (de)
MY (1) MY118068A (de)
NO (1) NO310196B1 (de)
NZ (1) NZ323571A (de)
PE (1) PE22798A1 (de)
PL (1) PL184715B1 (de)
RO (1) RO120074B1 (de)
SI (1) SI0776895T1 (de)
TR (1) TR199800759T2 (de)
TW (1) TW403754B (de)
UA (1) UA61897C2 (de)
WO (1) WO1997018809A1 (de)
YU (1) YU49315B (de)
ZA (1) ZA969646B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2485951C2 (ru) * 2007-12-21 2013-06-27 Новартис Аг Фармацевтическая композиция

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
DE69940423D1 (de) * 1998-01-30 2009-04-02 Daiso Co Ltd Verfahren zur herstellung von butantriol-derivaten
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6291446B1 (en) * 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
AU758241B2 (en) * 1998-03-13 2003-03-20 University Of British Columbia, The Granulatimide derivatives for use in cancer treatment
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
AU2001271614B2 (en) * 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
AU2001270252B2 (en) * 2000-07-03 2007-02-08 Catalent Pharma Solutions, Llc Expression vectors
US6300106B1 (en) * 2000-11-22 2001-10-09 Ppg Industries Ohio, Inc. Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
EP1501511A4 (de) * 2002-05-06 2006-06-07 Univ Washington Verfahren zur behandlung von glaukom und anderen erkrankungen, die durch nos-2 expression vermittelt werden, durch hemmung des egfr-wegs
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7232842B2 (en) * 2003-01-10 2007-06-19 Board Of Trustees Of The Leland Stanford Junior University Kinase inhibitors and associated pharmaceutical compositions and methods of use
WO2004111077A1 (en) * 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
US20050152942A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
NZ550340A (en) * 2004-03-17 2010-08-27 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle using a retinoid
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
WO2006071451A2 (en) * 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
WO2006068988A1 (en) * 2004-12-20 2006-06-29 Eli Lilly And Company Combination therapy for vascular complications associated with hyperglycemia
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
WO2008027619A2 (en) 2006-09-01 2008-03-06 Intermec Ip Corp. Rfid tag system with block coding, such as space-time block coding
EP2181999A1 (de) 2008-11-03 2010-05-05 Zentiva, A.S. Verfahren zur Herstellung von Ruboxistaurin
US9265764B2 (en) * 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
BR112012024585A2 (pt) 2010-03-30 2016-05-31 Novartis Ag inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas
PL2925366T3 (pl) 2012-11-29 2018-08-31 Novartis Ag Kombinacje farmaceutyczne
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2018118874A1 (en) 2016-12-19 2018-06-28 Chromaderm, Inc. Methods of treating hyperpigmentation disorders
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
IL297779A (en) 2020-05-01 2022-12-01 Applied Therapeutics Inc Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물
JP2025517412A (ja) 2022-05-20 2025-06-05 ダームビオント インコーポレイテッド 皮膚の疾患、疾病、および障害を予防、処置、かつ改善するためのｐｋ阻害薬の使用のための組成物および製剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
AU5100393A (en) * 1992-09-25 1994-04-26 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
CA2137203C (en) * 1993-12-07 2006-11-28 William Francis Heath Jr. Protein kinase c inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2485951C2 (ru) * 2007-12-21 2013-06-27 Новартис Аг Фармацевтическая композиция

Also Published As

Publication number Publication date
KR19990067596A (ko) 1999-08-25
IL124417A0 (en) 1998-12-06
PL326754A1 (en) 1998-10-26
CZ297524B6 (cs) 2007-01-03
EP0776895B1 (de) 1998-10-14
WO1997018809A1 (en) 1997-05-29
HUP9903377A3 (en) 2000-04-28
MX9803792A (es) 1998-09-30
AU1054897A (en) 1997-06-11
TR199800759T2 (xx) 2001-01-22
AR004336A1 (es) 1998-11-04
PE22798A1 (es) 1998-05-11
NO310196B1 (no) 2001-06-05
ZA969646B (en) 1998-05-18
AR004717A1 (es) 1999-03-10
JP3348859B2 (ja) 2002-11-20
CN1093759C (zh) 2002-11-06
SI0776895T1 (en) 1999-04-30
BR9611724A (pt) 1999-06-01
AU711125B2 (en) 1999-10-07
CY2103B1 (en) 2002-04-05
EA199800374A1 (ru) 1998-10-29
IL124417A (en) 2002-11-10
YU60996A (sh) 1999-03-04
HU226821B1 (en) 2009-11-30
NO982182D0 (no) 1998-05-13
CO4750823A1 (es) 1999-03-31
DK0776895T3 (da) 1999-06-23
ES2122764T3 (es) 1998-12-16
NO982182L (no) 1998-05-13
EG23871A (en) 2007-11-27
CA2237221A1 (en) 1997-05-29
EA000967B1 (ru) 2000-08-28
US6117861A (en) 2000-09-12
JPH11500149A (ja) 1999-01-06
RO120074B1 (ro) 2005-08-30
TW403754B (en) 2000-09-01
DE69600784T2 (de) 1999-04-08
MY118068A (en) 2004-08-30
US6015807A (en) 2000-01-18
CZ150298A3 (cs) 1998-12-16
PL184715B1 (pl) 2002-12-31
CA2237221C (en) 2003-03-25
US5710145A (en) 1998-01-20
ATE172199T1 (de) 1998-10-15
HUP9903377A2 (hu) 2000-02-28
KR100304210B1 (ko) 2001-11-05
NZ323571A (en) 1998-12-23
YU49315B (sh) 2005-06-10
EP0776895A1 (de) 1997-06-04
DE69600784D1 (de) 1998-11-19
CN1202825A (zh) 1998-12-23

Similar Documents

Publication Publication Date Title
UA61897C2 (en) Protein kinase c inhibitors, methods for synthesis, pharmaceutical formulations and methods for treating microvascular diabetic complications
CN115667226B (zh) 作为egfr抑制剂的三环化合物
JP7618338B2 (ja) ３－アザビシクロアルキル誘導体およびこれを含む薬剤学的組成物
CA3193341A1 (en) Compound as akt kinase inhibitor
WO2022166741A1 (zh) 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途
EP3841101B1 (de) Verfahren zur herstellung von 2-[(3r)-3-methylmorpholin-4-yl]4-[1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)1,7-naphthyridin
CN110248946B (zh) Menin-MLL相互作用的氮杂环庚烷抑制剂
AU701659B2 (en) Novel intermediates and their use to prepare n,n'-bridged bisindolylmaleimides
KR20250103668A (ko) 축합 이환 화합물
TW202218661A (zh) 作為ｅｇｆｒ抑制劑的三環化合物
US5721272A (en) Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
WO2019233434A1 (zh) 一种吡唑嘧啶衍生物及其用途和药物组合物
WO2025016391A1 (zh) 噻唑并吡嗪类化合物及其应用
TW202448857A (zh) 含有芳香二並環的化合物
CN120192307A (zh) 靶向p53突变的化合物